Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study)

被引:46
作者
Costa, Rogerio A.
Jorge, Rodrigo
Calucci, Daniela
Melo, Luiz A. S., Jr.
Cardillo, Jose A.
Scott, Ingrid U.
机构
[1] Hosp Olhos Araraquara, UDAT Macular Imaging & Treatment Div, BR-1801310 Araraquara, SP, Brazil
[2] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Ophthalmol, Retina & Vitreous Sect, BR-14049 Ribeirao Preto, SP, Brazil
[3] Penn State Univ, Coll Med, Dept Ophthalmol & Hlth Evaluat Sci, Hershey, PA USA
关键词
angiogenesis; laser; neovascularization; choroid; pegaptanib; ranibizumab; vascular endotelhial growth factor (VEGF); COHERENCE TOMOGRAPHY FINDINGS; TRIAMCINOLONE ACETONIDE; INJECTION; RANIBIZUMAB; OCCLUSION; SECONDARY; EDEMA; TRIAL; PDT;
D O I
10.1007/s00417-007-0557-x
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background A novel alternative for combined treatment using verteporfin photodynamic therapy (PDT) has emerged as preliminary safety and efficacy data of the intravitreal use of the anti-angiogenic bevacizumab became available. In the current study we investigate the feasibility of intravitreal bevacizumab combined with verteporfin PDT for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods A single-centre, prospective, open-label study of 11 patients with documented CNV progression after PDT treatment who underwent combined PDT and intravitreal injection of 1.5 mg of bevacizumab was undertaken. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 2, 12 and 24. Clinical evidence of complications and changes in logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and in fluorescein leakage from CNV were evaluated. Results The mean (+/- SD) age of the 11 patients was 74 (+/- 5) years. Seven eyes had been treated with one previous PDT session and four eyes had two previous PDT sessions. The mean baseline logMAR ETDRS BCVA was 1.031 (Snellen equivalent, 20/200(-2)). At follow-up weeks 1, 2, 12 and 24, the mean logMAR ETDRS BCVA (Snellen equivalent) was 0.944 (20/160(-2)), 0.924 (20/160(-1)), 0.882 (20/160(+1)), and 0.933 (20/160(-2)), respectively. The change in BCVA from baseline was significant at each study follow-up interval (P <= 0.001); at 12 and 24 weeks, the mean change in BCVA from baseline was an improvement of 1.49 and of 0.98 ETDRS line, respectively. Fluorescein leakage from CNV was absent in all eyes at week 12. One additional treatment session was required in seven (63.6%) eyes at week 24 due to recurrent fluorescein leakage from CNV ("minimum" [< 50% of the leaking area noted at baseline], n = 4; and "moderate" [> 50% of the leaking area noted at baseline], n = 3). No progression of the neovascular lesion was observed at week 24. No safety issues were identified throughout the period of the study. Conclusions The overall changes in vision and fluorescein leakage from CNV throughout the study suggest that a possible synergistic effect may arise from the combination of intravitreal bevacizumab with verteporfin PDT for the treatment of neovascular AMD.
引用
收藏
页码:1273 / 1280
页数:8
相关论文
共 49 条
[1]   Endophthalmitis with retinal necrosis following intravitreal triamcinolone acetonide injection [J].
Aggermann, T ;
Stolba, U ;
Brunner, S ;
Binder, S .
OPHTHALMOLOGICA, 2006, 220 (02) :131-133
[2]   Conjunctival ulceration following triamcinolone injection [J].
Agrawal, S ;
Agrawal, J ;
Agrawal, TP .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 136 (03) :539-540
[3]  
Arnold J, 2001, OPHTHALMOLOGY, V108, P841
[4]   Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration [J].
Avery, RL ;
Pieramici, DJ ;
Rabena, MD ;
Castellarin, AA ;
Nasir, MA ;
Giust, MJ .
OPHTHALMOLOGY, 2006, 113 (03) :363-372
[5]   AN INTERNATIONAL CLASSIFICATION AND GRADING SYSTEM FOR AGE-RELATED MACULOPATHY AND AGE-RELATED MACULAR DEGENERATION [J].
BIRD, AEC ;
BRESSLER, NM ;
BRESSLER, SB ;
CHISHOLM, IH ;
COSCAS, G ;
DAVIS, MD ;
DEJONG, PTVM ;
KLAVER, CCW ;
KLEIN, BEK ;
KLEIN, R ;
MITCHELL, P ;
SARKS, JP ;
SARKS, SH ;
SOURBANE, G ;
TAYLOR, HR ;
VINGERLING, JR .
SURVEY OF OPHTHALMOLOGY, 1995, 39 (05) :367-374
[6]   Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia - 2-year results of a randomized clinical Trial - VIP report no. 3 [J].
Blinder, KJ ;
Blumenkranz, MS ;
Bressler, NM ;
Bressler, SB ;
Donati, G ;
Lewis, H ;
Lim, JI ;
Menchini, U ;
Miller, JW ;
Mones, JM ;
Potter, MJ ;
Pournaras, C ;
Reaves, A ;
Rosenfeld, P ;
Schachat, AP ;
Schmidt-Erfurth, U ;
Sickenberg, M ;
Singerman, LJ ;
Slakter, J ;
Strong, HA ;
Virgili, G ;
Williams, GA .
OPHTHALMOLOGY, 2003, 110 (04) :667-673
[7]  
Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
[8]  
Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
[9]   Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].
Brown, David M. ;
Kaiser, Peter K. ;
Michels, Mark ;
Soubrane, Gisele ;
Heier, Jeffrey S. ;
Kim, Robert Y. ;
Sy, Judy P. ;
Schneider, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444
[10]   Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization [J].
Costa, RA ;
Farah, ME ;
Cardillo, JA ;
Calucci, D ;
Williams, GA .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2003, 23 (02) :159-165